Stem Cell Clinic

UFC Contender Cat Zingano Will Undergo Stem Cell Procedure for Left Knee

Top ranked UFC bantamweight challenger Cat Zingano has been out of action for several months due to an injury to her right knee. That injury is on the mend, but it has led to issues with her left knee, for which Zingano will have a procedure on Thursday.

I am about three and a half months out (from the original injury), Zingano said on UFC Tonight. I went to my doctor on Monday. He said that Im right on track, so I should be coming back in another four months, something like March or April.

That is, of course, as long as the issues with her left knee can be rectified within that same time frame, which her doctor believes is the case.

Dr. Ronald S. Kvitne of the Kerlan-Jobe Orthopedic Clinic in Los Angeles on Monday told Zingano that if there was a tear in her left meniscus, as expected, that if they act quickly, it shouldnt extend the rehab time of her original injury.

Dr. Kvitne was initially thinking a surgery would be necessary, but Zingano on Wednesday indicated that Thursdays procedure would instead involve a stem cell treatment.

My left knee, because I think for the compensation for taking care of my right knee, has been taking a little bit more wear and tear than it was used to, said Zingano.

So Im going to have a procedure done with stem cells (on Thursday) that is going to be in place of having clean-up surgery instead.

If Zinganos rehabilitation remains on schedule, she would be able to return to the Octagon and fight sometime around April of 2014.

We think three months from now shed be back in the ring training, sparring, said Kvitne. So fighting in about four to six months from now.

Zingano also told UFC Tonight that she should expect to fight the winner of the Dec. 28 rematch between current UFC bantamweight champion Ronda Rousey and challenger Miesha Tate upon her return.

View original post here:
UFC Contender Cat Zingano Will Undergo Stem Cell Procedure for Left Knee

FDA says StemCells can expand clinical trial to US

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix Beyond the Headline Local Popular Search Keyword News Search

See original here:
FDA says StemCells can expand clinical trial to US

Research on treatment for ALS aided by stem cells

Though the Food and Drug Administration remains closed due to the federal government shutdown, researchers at the University are pushing forward the development of stem-cell therapies, with the hope of improving the quality of life for individuals with life-threatening disabilities.

Researchers at University Hospital and the A. Alfred Taubman Medical Research Institute are exploring the use of stem cells in the treatment of amyotrophic lateral sclerosis also known as Lou Gerhigs disease, a neurodegenerative condition that causes cell death in spinal cord neurons that control movement. Patients with ALS suffer from loss of muscle control and often die of respiratory failure.

Neurology Prof. Eva Feldman presented recent results from her research at an event Wednesday evening at the Taubman Institutes Kahn Auditorium for an audience of about 40 students and faculty. Feldman discussed the completion of Phase I trials of the new stem-cell therapy and her plans for Phase II.

While Phase I trials typically test the safety of a treatment in human patients, Phase II tests the treatments efficacy. Feldmans research team received approval for Phase II of their research in May and has since begun tests.

Shortly before the event Wednesday afternoon, a third patient enrolled in the trial had the surgical procedure, in which a surgeon injects stem cells into specific regions of the spinal cord. Although it is too early to record changes in disease progression, Feldman said the three patients have experienced no adverse consequences from the procedure.

Stem cells have the unique ability to fulfill a wide variety of tasks by developing into specialized cells depending on their environment. When these cells are injected into the spinal cord of ALS patients, they surround diseased cells and slow the progression of cell death, Feldman said.

Depending on how you grow them they can become any cell in the body, Feldman said.

Feldmans treatment uses a relatively new strain of human embryonic stem cells developed at the University through partnerships with the National Institutes of Health. She referenced the work of Physiology Prof. Gary Smith at MStem Cell Laboratories the Universitys stem cell institution as a crucial component to the development of the treatment.

What weve done here at the University of Michigan is make embryonic stem cell lines, which are now being used for understanding disease course as well as for treatment, Feldman said.

Stem cells have the potential to aid in the treatment of not only ALS, but a wide range of debilitating and life-threatening diseases, including Parkinsons disease, Alzheimers disease and multiple sclerosis, Feldman said.

Read the rest here:
Research on treatment for ALS aided by stem cells

BrainStorm Launches US Activities for Its Multi-Center ALS Clinical Trial

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has launched its activities in the US in preparation for its Phase IIa multi-center clinical trial, with the initiation of the NurOwn technology transfer process at the Dana Farber Cancer Institute (DFCI). DFCIs Connell and O'Reilly Cell Manipulation Core Facility will produce NurOwn in its cGMP-compliant clean room facilities for the MGH and UMass Hospital clinical sites. The third clinical site in the trial, Mayo Clinic, will produce NurOwn at its own cleanroom facility.

We are very pleased with the progress we are making at DFCI, this being the final step for submission of the Company's IND application to the US FDA, commented Mr. Chaim Lebovits, BrainStorms President.

The Cell Manipulation Core Facility (CMCF) at Dana-Farber Cancer Institute (DFCI) is a manufacturing facility that produces safe and effective novel cellular component therapy that meets all regulatory guidelines for clinical use and also facilitates research to be translated from the bench to the bedside. All procedures are performed in environmentally controlled conditions according to current Good Manufacturing Practices (cGMP) for cell and tissue processing.

In 2012 BrainStorm successfully completed its first-in-man Phase I/II clinical study at Hadassah Medical Center in Jerusalem with 12 ALS patients, demonstrating initial indications of clinical benefit in six patients. BrainStorms Phase IIa dose-escalating trial at Hadassah is currently underway and the company will release the preliminary efficacy data at the conclusion of the trial.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as may, should, would, could, will, expect, likely, believe, plan, estimate, predict, potential, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorms forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or managements beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

See original here:
BrainStorm Launches US Activities for Its Multi-Center ALS Clinical Trial

Tendon treatment firm seeks new markets

Regenerative medicine company Orthocell has been recognised in a prestigious peer-reviewed journal for its tendon injury treatment, which uses stem cell technology.

The treatment, known as Autologous Tenocyte Implantation (ATI), involves taking a biopsy of the patient's healthy tendon, isolating and cultivating tendon stem cells from the tissue, then injecting them into the injured tendon.

The Perth-based company says the process takes about 20 minutes and is less invasive than surgery.

Professor Ming Hao Zheng of the University of Western Australia's Centre for Translational Orthopaedic Research, who led the development team, said treatment options for people suffering from tendon injury and related disorders were limited.

"There are no targeted drug therapies and surgery often delivers unsatisfactory results," Prof Zheng said.

But ATI has been hailed in the American Journal of Sports Medicine as a safe and effective procedure that repairs tendons and reduces the pain of conditions such as tennis elbow.

"This novel treatment is encouraging for the treatment of tendinopathy and warrants further evaluation," the journal concluded.

Orthocell managing director Paul Anderson said the company was now focused on offering the treatment more widely to patients throughout Australia and New Zealand, and was also investigating potential overseas markets.

Go here to see the original:
Tendon treatment firm seeks new markets

World-first Trial for Tendon Repair Using Tendon Stem Cells Published in the Prestigious American Journal of Sports …

PERTH, Australia, Oct. 2, 2013 /PRNewswire/ -- Regenerative medicine company, Orthocell Limited (Orthocell), today announced the results of its unprecedented and successful clinical trial for the treatment of tendon injuries using its patented stem cell technology. Tendon injuries are one of the most common causes of occupational and sporting disability and current clinical treatments are only moderately effective.

Orthocell's new technique is known as Autologous Tenocyte Implantation (Ortho-ATIT) and involves biopsy of the patient's own healthy tendon, isolation and cultivation of tendon stem cells from the biopsy in a special laboratory and then injection of these cells back to the injured tendon. The process takes about 20-minutes and is less invasive than surgery.

The company has received international profiling and recognition in the prestigious American Journal of Sports Medicine (AJSM), with a peer reviewed publication of the world first study on Ortho-ATIT stem cell technology for regeneration of damaged human tendon.

The AJSM, which is ranked as the world's number one journal for orthopaedics and sports medicine, published outcomes of the clinical trial last week. The data demonstrates that Orthocell's novel technology for repairing tendons was a safe and effective procedure that enables a reduction in pain and repairs tendon in severe chronic resistant tendon injury, like tennis elbow. The patients treated in the study, had failed at least one previous therapy including physiotherapy and corticosteroid injection. Patients achieved significant improvement in function and structural integrity of the tendon after the Ortho-ATIT tendon stem cell injection.

Orthocell Managing Director Paul Anderson said the clinical study indicates great potential for the Ortho-ATIT stem cell tendon repair.

"The AJSM paper is a benchmark study that validates the repair of tendon using tendon derived stem cells. We are now focussing our efforts on offering this world class treatment more widely to patients throughout Australasia, and we are also investigating new potential markets overseas," said Mr Anderson.

The technique was the result of more than 10 years development by Professor Ming Hao Zheng's group at the Centre for Translational Orthopaedic Research at the University of Western Australia, one of the top one hundred universities in the World.

"This is a very exciting body of work, which is indicated for a large patient population. There are currently limited treatment options for people suffering from tendon injury and related disorders, as there are no targeted drug therapies and surgery often delivers unsatisfactory results. This published study of Ortho-ATIT strongly suggested that substitution of tendon stem cells enables regeneration of tendon," said Professor Zheng.

Amanda Redwood, a 45-year-old mother of two who participated in the trial, said Orthocell's treatment relieved her of severe elbow pain within 6 months.

"I experienced debilitating symptoms of tennis elbow for more than 16-months before I had the procedure. Within 6 weeks of the injection the pain started to subside, and within 6 months it was gone," said Ms Redwood.

Link:
World-first Trial for Tendon Repair Using Tendon Stem Cells Published in the Prestigious American Journal of Sports ...

BioRestorative Engages Consulting Firm to Advance brtxDISC™ Program Delivery Device through FDA Clearance Process

JUPITER, Fla.--(BUSINESS WIRE)--

BioRestorative Therapies, Inc. ("BRT" or the "Company") (BRTX), a life sciences company focused on developing stem cell-based therapies for personal medical applications, announced the engagement of the regulatory consultancy firm Phil Triolo and Associates, LC (PTA) to help advance the Companys brtxDISC therapeutic procedure through the U.S. Food and Drug Administration (FDA) regulatory process. The brtxDISC program is the Companys non-surgical investigative treatment for bulging and herniated lumbar discs.

Under the engagement, PTA will assist the Company in its efforts to obtain U.S. regulatory approval and to satisfy FDA regulations applicable to the Companys medical device used in the brtxDISC procedure, including the implementation of quality systems procedures. In addition, PTA will assist BRT in its efforts to satisfy FDA regulations relevant to the combination products (biologic plus device) it ultimately plans to commercialize in the U.S. PTA is also available to assist in any international regulatory approval processes the Company may pursue.

This is an important step in advancing the development of our brtxDISC procedure, said Mark Weinreb, chief executive officer of BioRestorative Therapies. We have developed a minimally invasive, technologically innovative medical device to precisely deliver a patients own stem cells directly into the damaged region of the herniated and bulging disc, which is a key component of the success of the procedure.

There are approximately one million aggressive surgical back and spine procedures in the U.S. each year, including discectomies, disc replacements and spinal fusions. Our goal is to offer an alternative to these procedures by providing a cellular procedure to assist the patients body in repairing the disc. Pending regulatory approval, we look forward to commencing clinical trials in mid-2014, Mr. Weinreb added.

Phil Triolo and Associates, LC provides services to assure compliance with U.S. regulatory requirements during all stages of the product lifecycle, from feasibility, design and development, to manufacturing, post-production vigilance and audits.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including:

The Company also offers plant stem cell-based facial creams and beauty products under theStem Pearlsbrand atwww.stempearls.com.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Continue reading here:
BioRestorative Engages Consulting Firm to Advance brtxDISC™ Program Delivery Device through FDA Clearance Process

West Coast Stem Cell Clinic, TeleHealth, Now Offering Treatment with Stem Cells for Shoulder Arthritis and Tendonitis

Orange County, CA (PRWEB) October 02, 2013

The leading regenerative medicine clinic on the West Coast, TeleHealth, is now offering treatment with stem cells for shoulder arthritis and tendonitis. The treatments are performed as an outpatient and include autologous stem cell treatments that are derived from either bone marrow or fat along with PRP therapy. The treatments are often covered by insurance, and the doctors are Board Certified with years of experience in stem cell therapy. Call (888) 828-4575 for more information and scheduling.

Shoulder injuries are not frustrating just for high level athletes. Even individuals who perform overhead work, are involved in a car accident or simply dealing with degenerative arthritis may suffer from chronic shoulder pain. Traditional treatments may provide pain relief, however, prior to undergoing surgery regenerative medicine treatments should be considered with stem cell therapy.

TeleHealth offers Board Certified stem cell doctors treating shoulder pain with several options for stem cell therapy. This may include rotator cuff tendonitis, labral tears, shoulder joint arthritis, biceps tendonitis, rotator cuff tears or impingement syndrome. These may take many months to heal without stem cell treatment and there is a distinct possibility the injury may not heal due to the bodys inability to develop the repair response necessary.

The stem cell treatments offered at TeleHealth include platelet rich plasma therapy (PRP therapy) and autologous stem cell therapy from either bone marrow or fat. These treatment options may be combined to deliver the maximum effectiveness for healing response. The results to date have been impressive for speeding up healing response along with initiating healing in injuries that were unresponsive to traditional nonoperative options.

The treatments are often covered by insurance at TeleHealth, are low risk, and all performed by Board Certified doctors as an outpatient. For more information and scheduling, call (888) 828-4575.

See original here:
West Coast Stem Cell Clinic, TeleHealth, Now Offering Treatment with Stem Cells for Shoulder Arthritis and Tendonitis

Regenestem Announces Plans to Create a Stem Cell Treatment Center in Collaboration with CMC Hospital Group in Cozumel …

Miami, FL (PRWEB) October 02, 2013

Regenestem, a division of the Global Stem Cells Group, Inc., this week announced plans to create a stem cell treatment center in Cancun, Mexico that will offer the most advanced protocols and techniques in cellular medicine to patients from around the world.

The new Regenestem team in Cancun will be led by Rafael Moguel, M.D., a specialist in cardiology and interventional cardiology from Clinic of The Heart facility in Los Cabos, Mexico. An advocate and pioneer in the use of stem cell therapies to treat a wide variety of conditions, Moguel is joined by a team of talented and respected physicians from other Latin American countries and the U.S. to provide state-of-the-art patient treatment and follow-up under the Regenestem brand.

Regenestem currently offers stem cell treatments for arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes and multiple sclerosis at various facilities including Far Eastern University in Manila, Philippines, University of Nuevo Leon (University Hospital) in Monterrey, Mexico, and University Maimonides in Buenos Aires, Argentina.

Committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of its international patients, Regenestem provides an international staff and one-stop, cutting-edge cellular therapies focused on patient treatment.

All Regenestem facilities are certified for the medical tourism market, and staff physicians are board-certified or board-eligible and provide services in more than 10 specialties, attracting patients from the United States and around the world.

For more information, visit the Regenestem website, email info(at)regenstem(dot)com, or call 305-224-1858.

About Regenestem:

Regenestem, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.

About the Global Stem Cell Group:

Read more from the original source:
Regenestem Announces Plans to Create a Stem Cell Treatment Center in Collaboration with CMC Hospital Group in Cozumel ...